Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27711877 | 0.86 | KDM4E (0.44) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL84762 | 0.80 | MAOA (0.33) | HTR2AHTR2CKCNH2ALDH1A1KDM4E | |
| SCHEMBL803700 | 0.78 | NPC1 (0.48) | HTR2AHTR2CKCNH2KMT2AALDH1A1 | |
| SCHEMBL13286195 | 0.78 | KIF11 (0.41) | MEN1KMT2AALDH1A1KDM4EKIF11 | |
| SCHEMBL27791475 | 0.77 | S1PR1 (0.32) | HTR2AHTR2CKCNH2 | |
| SCHEMBL13792682 | 0.75 | KDM4E (0.49) | ALDH1A1KDM4EHPGD | |
| SCHEMBL50743 | 0.74 | PARP1 (0.46) | KMT2AALDH1A1KDM4EHPGDKIF11 | |
| SCHEMBL13965805 | 0.73 | CCNA2 (0.36) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL18661421 | 0.73 | CHEK2 (0.42) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL50237 | 0.72 | PARP1 (0.50) | MEN1KMT2AALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101918406-B | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2013-04-17 | — | — | CN | disclosed |
| CN-101918410-B | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL MYERS SQUIBB CO | 2013-02-27 | — | — | CN | disclosed |
| CN-101679441-B | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2012-11-14 | — | — | CN | disclosed |
| CN-101730698-B | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2012-09-05 | — | — | CN | disclosed |
| CN-101631790-B | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2012-07-18 | — | — | CN | disclosed |
| CN-101730698-A | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2010-06-09 | — | — | CN | disclosed |
| CN-101679442-A | The compound that is used for the treatment of hepatitis C | BRISTOL MYERS SQUIBB CO | 2010-03-24 | — | — | CN | disclosed |
| CN-101679441-A | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2010-03-24 | — | — | CN | disclosed |
| CN-101657455-A | Compounds for the treatment of hepatitis C | SQUIBB BRISTOL MYERS CO US | 2010-02-24 | — | — | CN | disclosed |
| CN-101646674-A | The indoles and the benzoazepine derivative that are used for the treatment of hepatitis C | SQUIBB BRISTOL MYERS CO US | 2010-02-10 | — | — | CN | disclosed |
| CN-101631790-A | The compound that is used for the treatment of hepatitis C | BRISTOL MYERS SQUIBB CO | 2010-01-20 | — | — | CN | disclosed |